Changing practice in systemic breast cancer, adjuvant treatment in a well-defined French population

Bulletin du Cancer

Volumn 86, Issue 10, 1999, Pages 855-860

  Chaplain, Gilles ^a   Coudert, Bruno ^b   Milan, Chantal ^c   Altwegg, Thierry ^d   Esteve, Jacques ^e  

^a UNIVERSITÉ DE BOURGOGNE   (France)

^b Centre G F Lecíerc   (France)

^c Registre des Tumeurs Digestives   (France)

^d Centre Radiotherapie du Parc   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Adjuvant treatment; Breast carcinoma; Cancer registry; Population based study; Practice patterns; Treatment trends

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RISK; CANCER SURVIVAL; EARLY DIAGNOSIS; FEMALE; FRANCE; HEALTH SERVICE; HUMAN; PROGNOSIS;

EID: 0032738694     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 1. Moller-Jensen O, Estève J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 11/12: 1167-256.
2. 2. Parkin DM, Muir CS, Whelan SL, Gao ST, Ferlay J, Powell J. Cancer incidence in five continents. Lyon: IARC Scientific Publications, 1992, vol. 120.
3. 3. Menegoz F, Black R, Arveux P, Magne V, Ferlay J, Buémi A, et al. Cancer incidence and mortality in France in 1975-1995. Eur J Cancer Prev 1997; 6: 442-66.
4. 4. Berrino F, Sant M, Verdecchia A, Capocaccia R, Hakulinen T, Estève J. Survival of cancer patients in Europe. The Eurocare study. Lyon: IARC Scientific publications, 1995, vol. 132.
5. 5. Eurocare. Protocol on care of cancer patients. A concerted action approved by the European Community. Coordinator F, Berrino. Lombardy Cancer Registry, 1992.
6. 6. NIH consensus conference. Adjuvant chemotherapy for breast cancer. Br Med J 1980; 281: 724-5.
7. 7. NIH consensus conference. Adjuvant chemotherapy for breast cancer. JAMA 1985; 254: 3461-3.
8. 8. Early Breast Cancer Trialist Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,696 women. N Engl J Med 1988; 319: 1681-92.
9. 9. Fisher B, Redmond C, Wicherham DL, Doxorubicin containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 1989; 7: 572-82.
10. 10. Early Breast Cancer Trialist Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992; 339: 1-15, 71-85.
11. 11. Bonnadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992; 52: 2127-37.
12. 12. National Cancer Institute. Treatment alert issued for node-negative breast cancer. J Natl Cancer Inst 1988; 80: 54-5.
13. 13. NIH consensus conference. Treatment of early-stage breast-cancer. JAMA 1991; 265: 391-5.
14. 14. Duffy SW, Tabar L, Fagerberg A, Gad O, Gröntoft M, South MC, et al. Breast screening, prognostic factors and survival - results from the Swedish two county study. Br J Cancer 1991; 64: 1113-38.
15. 15. Hopton DS, Thorogood J, Clayden AD, MacKinnon D. Observer variation in histological grading of breast cancer. Eur J Surg Oncol 1989; 15: 21-3.
16. 16. Theissig F, Kunze KD, Haroske G, Meyer W. Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract 1990; 186: 732-6.
17. 17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
18. 18. Burke HB, Henson DE. Histologic grade as a prognostic factor in breast carcinoma. Cancer 1997; 80: 1703-5.
19. 19. Roberti NE. The role of histologic grading in the prognosis of patients with carcinoma of the breast. Cancer 1997; 80: 1708-16.
20. 20. Sawka CA, O'Connor AM, Llewellyn-Thomas HA, To T, Pinfold SP, Harrison-Woermke D. Appropriateness of adjuvant systemic therapy for axillary node-negative breast cancer: a physician opinion survey. J Clin Oncol 1995; 13: 1459-69.
21. 21. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996; 66: 413-9.
22. 22. Olivotto IA, Bajdik CD, Math M, Plenderleith IM, Coppin CM, Phil D, et al. Adjuvant systemic treatment and survival after breast caner. N Engl J Med 1994; 330: 805-10.
23. 23. El M'rini T, Chaplain G, Tazi M, Bolard P, Milan C, Faivre J. Filic̀res de soins du traitement initial du cancer du sein en Côte-d'Or de 1982 à 1992. J Gyn Obst Biol Reprod 1998; 27: 495-500.
24. 24. ICD-O. International classification of disease. World Health Organisation (2nd ed.), Geneva: 1990.
25. 25. TNM. Classification of malignant tumors. 2nd revision (4th ed.), Berlin: Springer-Verlag, 1992, vol. 1.
26. 26. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
27. 27. Polednak AP, Flannery JT. Trends in breast cancer treatment in Connecticut. Connecticut Med 1993; 57: 59-64.
28. 28. Chaplain G, Barillot I, Cuisenier J, Milan C, Collin F, Dusserre P, et al. Facteurs ayant déterminé le choix entre mammectomie et traitement conservateur pour cancer du sein entre 1982 et 1990 dans le département de la Côte-d'Or. Bull Cancer 1994; 81: 303-10.
29. 29. BMDP. Statistical software manual. Berkeley. Los Angeles. Oxford: University of California Press, 1992, vol. 1 and 2.
30. 30. Institut national des statistiques et études économiques. Recensement 1990. Paris, 1991.